5α-reductase inhibitors: Preventing the treatable

European Urology

Volumn 62, Issue 2, 2012, Pages 242-244

  Hamilton, Robert J ^a   Andriole, Gerald L ^b   Freedland, Stephen J ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; FINASTERIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ANTICHOLINERGIC EFFECT; EDITORIAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GLEASON SCORE; GYNECOMASTIA; HEALTH CARE COST; HUMAN; LIBIDO; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SIDE EFFECT; URINE RETENTION;

5-ALPHA REDUCTASE INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 84862881659     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.04.016     Document Type: Editorial

References (14)

1. J.K. Parsons, J.M. Schenk, and K.B. Arnold Finasteride reduces the risk of incident clinical benign prostatic hyperplasia Eur Urol 62 2012 234 241
2. J.D. McConnell, C.G. Roehrborn, and O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398 (Pubitemid 37542987)
3. S.A. Kaplan, K. Walmsley, and A.E. Te Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia J Urol 179 2008 S82 S85
4. M. Gacci, G. Corona, and M. Salvi A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia Eur Urol 61 2012 994 1103
5. J. Izard, and J.C. Nickel Impact of medical therapy on transurethral resection of the prostate: two decades of change BJU Int 108 2011 89 93
6. A.R. Kristal, K.B. Arnold, and J.M. Schenk Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial J Urol 177 2007 1395 1400 quiz 1591 (Pubitemid 46436001)
7. J.D. McConnell, R. Bruskewitz, and P. Walsh The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group N Engl J Med 338 1998 557 563 (Pubitemid 28114643)
8. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224 (Pubitemid 36859473)
9. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
10. R.J. Hamilton, L.C. Kahwati, and L.S. Kinsinger Knowledge and use of finasteride for the prevention of prostate cancer Cancer Epidemiol Biomarkers Prev 19 2010 2164 2171
11. P. Albertsen, J.A. Hanley, and B.A. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101 (Pubitemid 40617061)
12. S.E. Eggener, P.T. Scardino, and P.C. Walsh Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185 2011 869 875
13. M.R. Theoret, Y.M. Ning, J.J. Zhang, R. Justice, P. Keegan, and R. Pazdur The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention N Engl J Med 365 2011 97 99
14. M. Marberger, S.J. Freedland, and G.L. Andriole Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study BJU Int 109 2012 1162 1169